Egypt
· Delayed Price · Currency is EGP Ibnsina Pharma Statistics
Total Valuation
Ibnsina Pharma has a market cap or net worth of EGP 3.68 billion. The enterprise value is 17.64 billion.
| Market Cap | 3.68B |
| Enterprise Value | 17.64B |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Ibnsina Pharma has 1.01 billion shares outstanding.
| Shares Outstanding | 1.01B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 25.94% |
| Owned by Institutions (%) | 23.67% |
| Float | 658.05M |
Valuation Ratios
The trailing PE ratio is 14.66 and the forward PE ratio is 9.13.
| PE Ratio | 14.66 |
| Forward PE | 9.13 |
| PS Ratio | 0.09 |
| PB Ratio | 2.25 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.35, with an EV/FCF ratio of -74.44.
| EV / Earnings | 70.29 |
| EV / Sales | 0.42 |
| EV / EBITDA | 10.35 |
| EV / EBIT | 11.78 |
| EV / FCF | -74.44 |
Financial Position
The company has a current ratio of 1.00, with a Debt / Equity ratio of 926.30.
| Current Ratio | 1.00 |
| Quick Ratio | 0.70 |
| Debt / Equity | 926.30 |
| Debt / EBITDA | 8.89 |
| Debt / FCF | -64.02 |
| Interest Coverage | 1.10 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 7.65M |
| Profits Per Employee | 45,630 |
| Employee Count | 5,500 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +74.53% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +74.53% |
| 50-Day Moving Average | 3.12 |
| 200-Day Moving Average | 3.01 |
| Relative Strength Index (RSI) | 66.34 |
| Average Volume (20 Days) | 10,850,220 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ibnsina Pharma had revenue of EGP 42.06 billion and earned 250.97 million in profits. Earnings per share was 0.25.
| Revenue | 42.06B |
| Gross Profit | 3.14B |
| Operating Income | 1.50B |
| Pretax Income | 351.11M |
| Net Income | 250.97M |
| EBITDA | 1.62B |
| EBIT | 1.50B |
| Earnings Per Share (EPS) | 0.25 |
Balance Sheet
The company has 1.21 billion in cash and 15.17 billion in debt, giving a net cash position of -13.96 billion or -13.85 per share.
| Cash & Cash Equivalents | 1.21B |
| Total Debt | 15.17B |
| Net Cash | -13.96B |
| Net Cash Per Share | -13.85 |
| Equity (Book Value) | 1.64B |
| Book Value Per Share | 1.62 |
| Working Capital | 11.90M |
Cash Flow
In the last 12 months, operating cash flow was 47.36 million and capital expenditures -284.35 million, giving a free cash flow of -236.99 million.
| Operating Cash Flow | 47.36M |
| Capital Expenditures | -284.35M |
| Free Cash Flow | -236.99M |
| FCF Per Share | -0.24 |
Margins
Gross margin is 7.47%, with operating and profit margins of 3.56% and 0.72%.
| Gross Margin | 7.47% |
| Operating Margin | 3.56% |
| Pretax Margin | 0.83% |
| Profit Margin | 0.72% |
| EBITDA Margin | 3.86% |
| EBIT Margin | 3.56% |
| FCF Margin | -0.56% |
Dividends & Yields
Ibnsina Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 8.45% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 6.82% |
| FCF Yield | -6.44% |
Stock Splits
The last stock split was on June 1, 2022. It was a forward split with a ratio of 1.16666.
| Last Split Date | Jun 1, 2022 |
| Split Type | Forward |
| Split Ratio | 1.16666 |